Seres Therapeutics, Inc. (NASDAQ:MCRB) Short Interest Up 92.9% in July

Seres Therapeutics, Inc. (NASDAQ:MCRB) was the recipient of a large growth in short interest in July. As of July 15th, there was short interest totaling 303,423 shares, a growth of 92.9% from the June 30th total of 157,327 shares. Based on an average trading volume of 151,675 shares, the short-interest ratio is presently 2.0 days. Approximately 3.3% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

MCRB has been the topic of a number of recent research reports. Wall Street Zen upgraded shares of Seres Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 6th. Zacks Research upgraded shares of Seres Therapeutics to a “hold” rating in a report on Tuesday, June 23rd. HC Wainwright initiated coverage on Seres Therapeutics in a research report on Tuesday, June 23rd. They issued a “buy” rating and a $12.00 price target on the stock. Finally, Weiss Ratings downgraded Seres Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 18th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $17.00.

Institutional Trading of Seres Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of MCRB. Bank of America Corp DE lifted its stake in shares of Seres Therapeutics by 2,772.6% during the 3rd quarter. Bank of America Corp DE now owns 5,343 shares of the biotechnology company’s stock valued at $103,000 after buying an additional 5,157 shares in the last quarter. Barclays PLC increased its stake in Seres Therapeutics by 427.8% in the 4th quarter. Barclays PLC now owns 7,432 shares of the biotechnology company’s stock worth $111,000 after buying an additional 6,024 shares in the last quarter. ExodusPoint Capital Management LP bought a new stake in Seres Therapeutics during the fourth quarter valued at about $190,000. Goldman Sachs Group Inc. bought a new stake in Seres Therapeutics during the fourth quarter valued at about $213,000. Finally, Invesco Ltd. lifted its position in shares of Seres Therapeutics by 37.5% in the fourth quarter. Invesco Ltd. now owns 14,360 shares of the biotechnology company’s stock valued at $214,000 after acquiring an additional 3,918 shares in the last quarter. 59.34% of the stock is currently owned by institutional investors.

Seres Therapeutics Trading Down 3.1%

Shares of MCRB stock opened at $4.65 on Thursday. Seres Therapeutics has a 12 month low of $4.59 and a 12 month high of $29.98. The company has a 50 day simple moving average of $6.57 and a two-hundred day simple moving average of $8.93. The stock has a market cap of $45.03 million, a P/E ratio of -0.90 and a beta of 0.09.

Seres Therapeutics (NASDAQ:MCRB) last released its earnings results on Tuesday, May 5th. The biotechnology company reported ($2.08) earnings per share for the quarter, missing the consensus estimate of ($1.88) by ($0.20). The company had revenue of $0.36 million during the quarter, compared to the consensus estimate of $0.36 million. As a group, equities analysts forecast that Seres Therapeutics will post -5.84 earnings per share for the current year.

Seres Therapeutics Company Profile

Seres Therapeutics is a clinical?stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.